Premium
Major Enteropathogenic Bacteria Isolated from Diarrheal Patients in Bolivia: A Hospital‐Based Study
Author(s) -
Utsunomiya Akiyoshi,
ElíoCalvo Daniel,
Reyes Armando Alberto Benitez,
Castro Ernesto Sanzetenea,
Rodríguez Enrique,
Tress Carolina,
Corzo Jenny I. Zamora,
Hannover Erika,
Kai Akemi,
Tamura Kazumichi,
Higa Naomi
Publication year - 1995
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1995.tb03281.x
Subject(s) - microbiology and biotechnology , shigella , serotype , biology , enteropathogenic escherichia coli , cholera , diarrhea , el tor , vibrio cholerae , trimethoprim , salmonella , virology , shigella flexneri , sulfamethoxazole , antibiotics , escherichia coli , bacteria , medicine , biochemistry , genetics , gene
A total of 1,234 fecal samples from diarrhea cases were examined for etiological bacterial agents at medical facilities in La Paz and Sucre, Bolivia. Eighty strains of Shigella spp., 39 strains of Salmonella spp., 29 strains of Vibrio cholerae , and 222 strains of enteropathogenic Escherichia coli (139 EPEC, 55 ETEC, 29 EIEC, and 1 EHEC) were isolated. With regard to the serovars of Shigella, S. flexneri 2a, 3a, and 1b were predominant. In the case of Salmonella, S. enteritidis was the most common, followed by S. typhi, S. poona , and S. paratyphi B. Out of 29 cholera strains, 25 belonged to biovar El Tor, serovar Ogawa while the remaining 4 were serovar Inaba. Among 55 strains of ETEC serotypes, 5 showed ST producers but none showed LT producers. Likewise, among 55 strains of enterohemorrhagic serotypes, only one strain (O157:H7) produced verocytotoxin (VT 2). The results of drug sensitivity tests revealed the predominance of Shigella , EPEC, and ETEC strains resistant to aminobenzil‐penicillin (ABPC) and trimethoprim. Since diarrheal patients in Bolivia are treated mainly with ABPC or sulfamethoxazole/trimethoprim (SXT) and rarely with gentamicin, kanamycin, or other drugs, it is possible that ABPC‐ and SXT‐resistant strains will increase and persist in the near future.